International Medical Journal, Vol. 21., Iss. 1, 2015, P. 5−11.
CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (BARCELONA, 2014): RESULTS OF THE MOST IMPORTANT CLINICAL TRIALS
Kuban State Medical University, Ministry of Health of Russian Federation, Krasnodar, Russian Federation
The latest Congress of the European Society of Cardiology was held this year in Barcelona, Spain. More than 30 thousand participants were able to learn about the latest developments of cardiology, which were presented at Hot Line sessions of the Congress under the overall theme of «Innovation and Heart». Session 1 «Cardiovascular disease: novel therapies» showed the findings of investigation of the advantages of a new drug LCZ696 in treatment of chronic heart failure; the feasibility of intravenous iron preparations on identification of its deficiency; the use of Сolchicine in cardiac surgery. Session 2 «Coronary artery disease and lipids» covered the results of the use of Darapladib, Ivabradine, alirokumab, Rosuvastin. Session 3 «Heart failure: devices and interventions» presented a study on improving the design of drug−eluting stents, a comparison of the cost of management of patients with cardioverter−defibrillator randomized to use the technology of home monitoring. Session 4 «Myocardial infarction» acquainted with the results of percutaneous coronary intervention in patients with myocardial infarction, effects of Ticagrelor effects at pre−hospital and hospital stages, evaluation of the drug TRO40303. Session 5 «Coronary artery disease and atrial fibrillation» reported the data on perioperative statin therapy reducing atrial fibrillation, long−term results of short−term antiarrhythmic therapy after catheter ablation of atrial fibrillation, the effect of prednisolone and immunotherapy on patients with tuberculous pericarditis.
Key words: cardiovascular diseases, clinical trials, Hot Line sessions.